(NASDAQ: PAHC) Phibro Animal Health's forecast annual revenue growth rate of 3.63% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 15.18%.
Phibro Animal Health's revenue in 2026 is $1,464,325,000.On average, 6 Wall Street analysts forecast PAHC's revenue for 2026 to be $61,491,164,172, with the lowest PAHC revenue forecast at $58,613,199,336, and the highest PAHC revenue forecast at $63,761,108,268. On average, 6 Wall Street analysts forecast PAHC's revenue for 2027 to be $63,842,177,700, with the lowest PAHC revenue forecast at $60,761,539,284, and the highest PAHC revenue forecast at $66,031,052,364.
In 2028, PAHC is forecast to generate $65,868,913,500 in revenue, with the lowest revenue forecast at $62,747,740,368 and the highest revenue forecast at $68,260,461,744.